Galapagos NV (GLPG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Galapagos NV (GLPG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH82206D
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Galapagos NV (Galapagos) is a clinical stage biotechnology company that discovers and develops pharmaceutical products. The company's product pipeline encompasses investigational candidates targeted at the treatment of rheumatoid arthritis in Phase 3, Crohn's in Phase 2, ulcerative colitis in Phase 2, idiopathic pulmonary fibrosis (IPF) in Phase 2, osteoarthritis in Phase 1, inflammation in Phase 1, and two candidates against cystic fibrosis in Phase 1 and 2. The company works in collaboration with pharma companies for its research activities. The company has presence in the UK, the Netherlands, Croatia, the US, Japan and Hong Kong. Galapagos is headquartered in Mechelen, Belgium.

Galapagos NV (GLPG)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Galapagos NV, Medical Devices Deals, 2011 to YTD 2017 10

Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Galapagos NV, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Pharnext Enters into Research Agreement with Galapagos 13

Gilead Sciences Enters into Co-Development Agreement with Galapagos 13

Calchan Enters into Research Partnership with Galapagos 14

Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 15

AbbVie Expands its Agreement with Galapagos 16

Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 17

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 18

Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos 19

NovAliX Enters Into Drug Discovery Agreement With Galapagos 20

Licensing Agreements 21

ThromboGenics Enters into Licensing Agreement with Galapagos 21

Galapagos Enters into Licensing Agreement with HUB foundation 22

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 22

Equity Offering 23

Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 23

Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 25

Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 26

Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 26

Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 27

Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 28

Galapagos Raises USD425 Million in Private Placement of Shares 29

Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 30

Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 30

Galapagos Raises USD240 Million in Public Offering of Shares 31

Galapagos Raises USD74.5 Million in Private Placement of Shares 33

Galapagos to Raise Funds through Private Placement 34

Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 35

Galapagos Completes Private Placement Of Shares For US$2.2 Million Upon Exercise Of Warrants 36

Galapagos Completes Private Placement Of Shares For US$70 Million 37

Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 38

Galapagos Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 38

Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 39

Asset Transactions 40

Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 40

Acquisition 41

Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 41

Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For US$179 Million 42

Galapagos Acquires Cangenix, Drug Discovery Company, For Up To US$2.3 Million 44

Evotec Acquires Compound Focus 44

Galapagos NV-Key Competitors 46

Key Employees 47

Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Recent Developments 49

Financial Announcements 49

Feb 23, 2017: Galapagos reports strong financial results and newsflow-rich pipeline 49

Oct 27, 2016: Galapagos: Robust progress in Q3 2016 51

Jul 28, 2016: Focus on filgotinib and cystic fibrosis 52

Apr 28, 2016: Galapagos kick-starts 2016 with Q1 cash position of EU988 M 53

Corporate Communications 54

Jan 17, 2017: Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer 54

Product News 55

Jan 19, 2016: Galapagos advances CF clinical development 55

Product Approvals 56

May 24, 2016: Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) 56

Clinical Trials 57

May 25, 2016: FITZROY Phase 2 study with filgotinib in Crohns Disease presented as late breaker at DDW 2016 57

May 09, 2016: Galapagos starts Phase 1 study with potentiator GLPG2451 for CF 58

Apr 21, 2016: Galapagos reports additional data with filgotinib from the Phase 2 FITZROY study 59

Mar 18, 2016: Results from 10-week analysis of Phase 2 study with filgotinib in Crohn Disease presented at ECCO 60

Other Significant Developments 61

Jun 15, 2016: Galapagos provides R&D Update 2016 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62

List of Figures

Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Galapagos NV, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Galapagos NV, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Galapagos NV, Deals By Therapy Area, 2011 to YTD 2017 9

Galapagos NV, Medical Devices Deals, 2011 to YTD 2017 10

Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Pharnext Enters into Research Agreement with Galapagos 13

Gilead Sciences Enters into Co-Development Agreement with Galapagos 13

Calchan Enters into Research Partnership with Galapagos 14

Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 15

AbbVie Expands its Agreement with Galapagos 16

Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 17

Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 18

Les Laboratoires Servier Enters Into Co-Development Agreement With Galapagos 19

NovAliX Enters Into Drug Discovery Agreement With Galapagos 20

ThromboGenics Enters into Licensing Agreement with Galapagos 21

Galapagos Enters into Licensing Agreement with HUB foundation 22

GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 22

Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 23

Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 25

Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 26

Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 26

Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 27

Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 28

Galapagos Raises USD425 Million in Private Placement of Shares 29

Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 30

Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 30

Galapagos Raises USD240 Million in Public Offering of Shares 31

Galapagos Raises USD74.5 Million in Private Placement of Shares 33

Galapagos to Raise Funds through Private Placement 34

Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 35

Galapagos Completes Private Placement Of Shares For US$2.2 Million Upon Exercise Of Warrants 36

Galapagos Completes Private Placement Of Shares For US$70 Million 37

Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 38

Galapagos Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 38

Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 39

Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 40

Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 41

Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For US$179 Million 42

Galapagos Acquires Cangenix, Drug Discovery Company, For Up To US$2.3 Million 44

Evotec Acquires Compound Focus 44

Galapagos NV, Key Competitors 46

Galapagos NV, Key Employees 47

Galapagos NV, Subsidiaries 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Galapagos NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16145
Site License
USD 500 INR 32290
Corporate User License
USD 750 INR 48435

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com